Generally, Nrf2 activation is a negative prognostic factor in cancer; indeed, it is involved in several key cancer-supportive functions, including cancer cells proliferation through the upregulation of anabolic metabolism and by acting on epidermal growth factor receptor signaling. This evidence concerns the gene NFE2L2 and cancer.